(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide

CAS: 439081-18-2

Ref. 3D-PSA08118

Produktinformation

• Name: (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide
• Synonyme: (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl}-4-(dimethylamino)but-2-enamide, (E)-N-(7-((S)-tetrahydrofuran-3-yloxy)-4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide, (S,E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-dime, 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-, Afatinib, Bibw 2992, Bibw2992, N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide, Tovok
• CAS: 439081-18-2

Beschreibung

LFM-A13 is a small molecule that has shown potential to be a biomarker for cancer. This drug has been shown to inhibit the activity of pro-apoptotic proteins and induce the production of cytokines in vitro. LFM-A13 also reduces tumor size in vivo by interfering with receptor activity in solid tumours. LFM-A13 has also shown antiviral properties, inhibiting the growth of HIV and influenza A virus in vitro.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 485.95 g/mol
• Formel: C₂₄H₂₅ClFN₅O₃
• Reinheit: Min. 95%